UBS Group AG Grows Position in Zura Bio Limited $ZURA

UBS Group AG boosted its stake in shares of Zura Bio Limited (NASDAQ:ZURA) by 54.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,540 shares of the company’s stock after buying an additional 165,211 shares during the quarter. UBS Group AG owned approximately 0.72% of Zura Bio worth $2,466,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZURA. Bank of America Corp DE lifted its holdings in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares in the last quarter. AQR Capital Management LLC bought a new stake in Zura Bio during the 1st quarter valued at about $72,000. JPMorgan Chase & Co. lifted its holdings in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Jane Street Group LLC bought a new stake in Zura Bio during the 2nd quarter valued at about $113,000. Finally, Atika Capital Management LLC bought a new stake in Zura Bio during the 3rd quarter valued at about $1,195,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $4.21 on Wednesday. Zura Bio Limited has a one year low of $0.98 and a one year high of $7.44. The firm has a market cap of $399.45 million, a P/E ratio of -3.86 and a beta of 0.09. The firm has a 50-day simple moving average of $5.33 and a 200-day simple moving average of $5.24.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). On average, research analysts predict that Zura Bio Limited will post -0.73 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Wedbush assumed coverage on shares of Zura Bio in a report on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective for the company. Chardan Capital lifted their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Finally, Oppenheimer decreased their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Insider Activity at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the acquisition, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 22.10% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.